Przecież stoi wyżej jak byk, że jest trawiony do peptydów kolagenowych

Role of collagen hydrolysate in bone and joint disease
Roland W. Moskowitz
Seminars in Arthritis and Rheumatism
Volume 30, Issue 2 , October 2000, Pages 87-99
Abstract
Objectives: To review the current status of collagen hydrolysate in the
treatment of osteoarthritis and osteoporosis. Methods: Review of past and
current literature relative to collagen hydrolysate metabolism, and assessment
of clinical investigations of therapeutic trials in osteoarthritis and
osteoporosis. Results: Hydrolyzed gelatin products have long been used in
pharmaceuticals and foods; these products are generally recognized as safe food
products by regulatory agencies. Pharmaceutical-grade collagen hydrolysate (PCH)
is obtained by hydrolysis of pharmaceutical gelatin. Clinical studies suggest
that the ingestion of 10 g PCH daily reduces pain in patients with
osteoarthritis of the knee or hip; blood concentration of hydroxyproline is
increased. Clinical use is associated with minimal adverse effects, mainly
gastrointestinal, characterized by fullness or unpleasant taste. In a
multicenter, randomized, double-blind, placebo-controlled trial performed in
clinics in the United States, United Kingdom, and Germany, results showed no
statistically significant differences for the total study group (all sites) for
differences of mean pain score for pain. There was, however, a significant
treatment advantage of PCH over placebo in German sites. In addition, increased
efficacy for PCH as compared to placebo was observed in the overall study
population amongst patients with more severe symptomatology at study onset.
Preferential accumulation of 14C-labeled gelatin hydrolysate in cartilage as
compared with administration of 14C-labeled proline has been reported. This
preferential uptake by cartilage suggests that PCH may have a salutary effect on
cartilage metabolism. Given the important role for collagen in bone structure,
the effect of PCH on bone metabolism in osteoporotic persons has been evaluated.
Studies of the effects of calcitonin with and without a collagen
hydrolysate-rich diet suggested that calcitonin plus PCH had a greater effect in
inhibiting bone collagen breakdown than calcitonin alone, as characterized by a
fall in levels of urinary pyridinoline cross-links. PCH appeared to have an
additive effect relative to use of calcitonin alone. Conclusions: Collagen
hydrolysate is of interest as a therapeutic agent of potential utility in the
treatment of osteoarthritis and osteoporosis. Its high level of safety makes it
attractive as an agent for long-term use in these chronic disorders.